Amazon introduced the Amazon Bio Discovery service to speed early drug discovery

AWS has launched Amazon Bio Discovery — a new AI platform for the early stage of drug development. The service is designed to shorten the path from scientific hypothesis to a list of molecules ready for laboratory testing, and remove some of the manual work between computational biology and "wet" laboratory.

How the service works

Amazon Web Services announced the launch of Amazon Bio Discovery on April 14, 2026. The platform is designed for pharmaceutical and biotech companies looking for candidates for new drugs, and especially focuses on antibody-related tasks. Instead of deploying separate models, pipelines, and infrastructure manually, researchers get a ready-made environment where they can run computational experiments, compare results, and prepare candidates for the next testing phase.

The key idea of the service is a lab-in-the-loop approach, where computational design is not separated from actual laboratory tests. First, scientists formulate a research goal and upload the target structure, then AI agents help select the right models, parameters, and selection criteria. After that, the system generates and ranks molecules by binding probability, structural confidence, and other characteristics. The best candidates can be sent to laboratory partners for synthesis and testing, and the results obtained are returned to the platform for analysis and the next iteration.

What's inside the platform

According to AWS, Amazon Bio Discovery brings together in one interface the stages that in real R&D teams are usually spread across multiple services, scripts, and specialists. The idea is that a biologist or research group doesn't have to separately search for the right model, configure the environment, build a pipeline, and manually transfer results between the computational part and the laboratory each time.

• a catalog of more than 40 specialized AI models for early-stage drug discovery tasks
• AI agents for model selection, experiment configuration, and candidate evaluation
• a multi-step pipeline builder where you can connect your own company models
• integration with laboratory partners for synthesis and biological testing
• automatic return of experimental data to the system for retraining and refining predictions

AWS is betting not just on speed, but on the ability for these tools to be used not only by computational biologists. The company directly points to a typical market problem: new biological AI models appear too quickly, and specialists who know how to implement and maintain them become a bottleneck. For laboratory scientists, this translates into slow access to experiments that could be run much earlier.

First results and clients

The most notable case at launch is Memorial Sloan Kettering Cancer Center. The center used Amazon Bio Discovery to accelerate the development of antibodies against pediatric oncological diseases. According to AWS, with the help of AI agents, researchers designed almost 300,000 new antibody molecules and sent 100,000 of the best candidates for testing. A process that with a traditional approach could take up to a year was reduced to a few weeks in this scenario.

"Amazon

Bio Discovery provides a convenient solution for applying new AI models in the design and evaluation of new molecules."

Among early users, AWS also names Bayer, Broad Institute, and Voyager Therapeutics. Special emphasis has been placed on corporate security: proprietary data and fine-tuned client models are isolated within their environment, and the data itself, according to AWS, is not used to train hosted models. For pharma, this is one of the key conditions, because without data protection and intellectual property protection, the transfer of sensitive R&D processes to a cloud platform is usually hindered as much as by the lack of computing resources.

What this means

Amazon is trying to establish a more prominent position not only as a cloud provider for pharma, but also as a practical player in AI-driven drug development. If the platform really does reduce the time between computational design and laboratory validation, biotech teams will have a chance to test hypotheses faster, and AWS will establish itself in one of the most expensive and competitive segments of the AI market.